Enjoy complimentary customisation on priority with our Enterprise License!
Biosimilars are generally the lower-priced versions of reference products. As a result, they are launched in the market to reduce the costs and benefit the patients. Technavio’s market research report identifies that the increasing number of biosimilars, generics, and specialty drugs will be one of the primary growth drivers for the global pharmacy benefit management market until 2021. The purchase volume of generics is increasing because it enables patients to access the same treatment provided by reference products at much lower prices. This is encouraging vendors to come up with best benefit plans. Vendors are also focusing on obtaining incentives from other stakeholders. The scope for pharmacy benefit management (PBM) is also increasing with the rising number of enrolments in health pharmacy benefits plans. According to the pharmacy benefit management market analysis, this market will grow at a CAGR of more than 6% by 2021.
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: MARKET LANDSCAPE
PART 05: MARKET SIZING
PART 06: FIVE FORCES ANALYSIS
PART 07: CUSTOMER LANDSCAPE
PART 08: SEGMENTATION BY TYPE OF SERVICE
PART 09: REGIONAL LANDSCAPE
PART 10: DECISION FRAMEWORK
PART 11: DRIVERS AND CHALLENGES
PART 12: MARKET TRENDS
PART 13: VENDOR LANDSCAPE
PART 14: VENDOR ANALYSIS
PART 15: APPENDIX
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.